Page 250 - 2022_01-Haematologica-web

C. Pawlyn et al.
myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(12):e616-e629.
17. Royston P, Lambert PC. Flexible parametric survival analysis using stata: beyond the Cox model. College Station, Tex. Stata, 2011.
18. https://www.ons.gov.uk/peoplepopulatio- nandcommunity/birthsdeathsandmar- riages/lifeexpectancies/datasets/nationallifet ablesunitedkingdomreferencetables. (Last accessed Feb 2017).
19. Cook G, Royle KL, Pawlyn C, et al. A clini- cal prediction model for outcome and thera- py delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019;6(3):e154-e166.
20. Boyle EM, Proszek PZ, Kaiser MF, et al. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typ- ical of presenting myeloma. Genes Chromosomes Cancer. 2015;54(2):91-98.
21. Kaiser MF, Walker BA, Hockley SL, et al. A TC classification-based predictor for multi- ple myeloma using multiplexed real-time quantitative PCR. Leukemia. 2013;27(8): 1754-1757.
22. Boyd KD, Ross FM, Chiecchio L, et al. A
novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349-355.
23. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high- risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.
concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910- 921.
28.Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autolo- gous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20(3):402-408.
24.
Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in eld- erly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114(3):600- 607.
25.Auner HW, Iacobelli S, Sbianchi G, et al. Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;103(3): 514-521.
26. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074.
27. Engelhardt M, Domm AS, Dold SM, et al. A
30.Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dex- amethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115.
31. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melpha- lan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518-528.
32. Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diag- nosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132-141.
29.
Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexametha- sone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311-1320.
242
haematologica | 2022; 107(1)